CD274 and triple-negative breast carcinoma: It is worth noting that in 2019, based on the IMpassion130 trial, the U.S. FDA granted accelerated approval to atezolizumab, a humanized anti‐PD‐L1 monoclonal antibody, in combination with nab‐paclitaxel for treatment of advanced triple negative breast cancer (TNBC) patients, whose tumours show PD‐L1 positivity by IHC tests from immune cells.13